MCF Advisors LLC Makes New Investment in 10x Genomics, Inc. (NASDAQ:TXG)

MCF Advisors LLC acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,431 shares of the company’s stock, valued at approximately $92,000.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after buying an additional 1,265 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of 10x Genomics in the third quarter valued at $35,000. Blue Trust Inc. raised its stake in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after acquiring an additional 1,025 shares in the last quarter. Sound Income Strategies LLC acquired a new position in 10x Genomics during the 3rd quarter worth $46,000. Finally, Venturi Wealth Management LLC increased its holdings in 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after purchasing an additional 2,240 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group decreased their price objective on 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, October 10th. The Goldman Sachs Group lowered their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. Barclays reduced their price objective on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Morgan Stanley decreased their price objective on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Finally, Citigroup cut their price target on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.86.

10x Genomics Stock Up 0.9 %

TXG opened at $16.31 on Thursday. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $51.22. The business’s 50 day moving average is $14.98 and its two-hundred day moving average is $17.89. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -10.66 and a beta of 1.83.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. The business had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.51) EPS. Equities analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.